August 11, 2009
A large effectiveness study comparing Schering-Plough's pegylated-interferon Pegintron and ribavirin with Roche's Pegasys and ribavirin shows both hepatitis C treatments worked equally well.
The study by Dr. Mark Sulkowski of Johns Hopkins University involved 3,000 patients with hepatitis C. Its findings are meant to help guide doctors' decisions about which treatments work best.
"There has been a lot of debate about these two regimens," said Dr. Andrew Muir of Duke University, a co-author of the Schering-Plough-funded study. "It's great to have a study of this size that really answers this question."
07.22.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|The Future of 2-Drug Regimens for People With HIV|
|Do People With HIV Need Annual Physical Examinations?|
|Liquor Tied to Gut Integrity and Inflammation in Adults With HIV|
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: New Discovery in How HIV Hijacks a Cell|
|Impact of HIV, Age and Comorbidity on Depression and Quality of Life|